GTS
MCID: GLL008
MIFTS: 67

Gilles De La Tourette Syndrome (GTS)

Categories: Mental diseases, Neuronal diseases, Oral diseases, Rare diseases, Smell/Taste diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

MalaCards integrated aliases for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 56 12 25 73 13 15 39 71
Tourette Syndrome 56 12 74 52 25 53 36 29 54 6 42 3 43 15 17
Gilles De La Tourette's Syndrome 74 52 25
Tourette Disorder 56 52 25
Gts 56 25 73
Ts 56 25 3
Chronic Motor and Vocal Tic Disorder 25
Motor-Verbal Tic Disorder 12
Tourette Syndrome; Ts 56
Tourette's Syndrome 52
Tourette's Disease 25
Guinon's Disease 12
Psychogenic Tics 12
Td 25

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
male:female ratio 4:1
onset ages 2 to 14 years


HPO:

31
gilles de la tourette syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11119
OMIM 56 137580
KEGG 36 H00862
ICD9CM 34 307.23
MeSH 43 D005879
NCIt 49 C35078
SNOMED-CT 67 39098006 5158005
ICD10 32 F95.2
UMLS 71 C0040517

Summaries for Gilles De La Tourette Syndrome

Genetics Home Reference : 25 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood. Tourette syndrome involves both motor tics, which are uncontrolled body movements, and vocal or phonic tics, which are outbursts of sound. Some motor tics are simple and involve only one muscle group. Simple motor tics, such as rapid eye blinking, shoulder shrugging, or nose twitching, are usually the first signs of Tourette syndrome. Motor tics also can be complex (involving multiple muscle groups), such as jumping, kicking, hopping, or spinning. Vocal tics, which generally appear later than motor tics, also can be simple or complex. Simple vocal tics include grunting, sniffing, and throat-clearing. More complex vocalizations include repeating the words of others (echolalia) or repeating one's own words (palilalia). The involuntary use of inappropriate or obscene language (coprolalia) is possible, but uncommon, among people with Tourette syndrome. In addition to frequent tics, people with Tourette syndrome are at risk for associated problems including attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), anxiety, depression, and problems with sleep.

MalaCards based summary : Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to asperger syndrome and tic disorder, and has symptoms including seizures, tremor and back pain. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways/superpathways are Histidine metabolism and Circadian entrainment. The drugs Guanfacine and Clonidine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and cortex, and related phenotypes are sleep disturbance and attention deficit hyperactivity disorder

Disease Ontology : 12 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

NIH Rare Diseases : 52 Tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. Tourette syndrome is named for Georges Gilles de la Tourette, who first described this disorder in 1885. A variety of genetic and environmental factors likely play a role in causing Tourette syndrome. A small number of people with Tourette syndrome have been found to have mutations involving the SLITRK1 gene . The syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. It is estimated that about 1% of the population has Tourette syndrome. Many people with very mild tics may not be aware of them and never seek medical help. Tourette syndrome is four times as likely to occur in boys as in girls. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

OMIM : 56 Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with behavioral abnormalities. Tics are sudden, brief, intermittent, involuntary or semi-voluntary movements (motor tics) or sounds (phonic or vocal tics). They typically consist of simple, coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. Motor tics may range from simple blinking, nose twitching, and head jerking to more complex throwing, hitting, or making rude gestures. Phonic tics include sniffling, throat clearing, blowing, coughing, echolalia, or coprolalia. Males are affected about 3 times more often than females, and onset usually occurs between 3 and 8 years of age. By age 18 years, more than half of affected individuals are free of tics, but they may persist into adulthood (review by Jankovic, 2001). (137580)

MedlinePlus : 42 If you have Tourette syndrome, you make unusual movements or sounds, called tics. You have little or no control over them. Common tics are throat-clearing and blinking. You may repeat words, spin, or, rarely, blurt out swear words. Tourette syndrome is a disorder of the nervous system. It often occurs with other problems, such as Attention deficit hyperactivity disorder (ADHD) Obsessive-compulsive disorder (OCD) Anxiety Depression The cause of Tourette syndrome is unknown. It is more common in boys than girls. The tics usually start in childhood and may be worst in the early teens. Many people eventually outgrow them. No treatment is needed unless the tics interfere with everyday life. Excitement or worry can make tics worse. Calm, focused activities may make them better. Medicines and talk therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Tourette Syndrome (TS) is a condition of the nervous system. TS causes people to have "tics". Tics are sudden twitches, movements, or sounds that people do repeatedly. People who have tics cannot stop their body from doing these things. For example, a person might keep blinking over and over again. Or, a person might make a grunting sound unwillingly. Having tics is a little bit like having hiccups. Even though you might not want to hiccup, your body does it anyway. Sometimes people can stop themselves from doing a certain tic for awhile, but it's hard. Eventually the person has to do the tic.

NINDS : 53 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood.  Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others).  Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

KEGG : 36 Tourette's syndrome (TS) is a developmental neuropsychiatric disorder characterized by chronic motor and vocal tics. Rare functional variants in the neuronal transmembrane molecule SLITRK1 have been associated with TS. The SLITRK1 gene is expressed in brain regions and it appears to play a role in dendritic growth. Another possible rare genetic cause of TS is a mutation in the HDC gene. The HDC gene encodes for L-histidine decarboxylase, which is the rate-limiting enzyme that catalyzes the biosynthesis of histamine from histidine.

UniProtKB/Swiss-Prot : 73 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

Wikipedia : 74 Tourette syndrome (TS or simply Tourette's) is a common neurodevelopmental disorder with onset in... more...

Related Diseases for Gilles De La Tourette Syndrome

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 658)
# Related Disease Score Top Affiliating Genes
1 asperger syndrome 33.0 SGCE COMT BDNF
2 tic disorder 32.5 SLITRK1 SLC6A3 IMMP2L HDC DRD5 DRD4
3 obsessive-compulsive disorder 32.3 SLITRK1 SLC6A3 SGCE DRD4 DRD2 COMT
4 tardive dyskinesia 32.0 DRD2 COMT
5 movement disease 31.8 TH SLC6A3 SGCE DRD5 DRD4 DRD2
6 echolalia 31.8 GTSCR1 CNTNAP2
7 attention deficit-hyperactivity disorder 31.7 TH SLC6A3 SLC1A3 IMMP2L DRD5 DRD4
8 avoidant personality disorder 31.7 SLC6A3 DRD4 DRD2
9 choreatic disease 31.6 SGCE DRD5 DRD4 DRD2 CNTNAP2 BDNF
10 focal dystonia 31.6 SGCE DRD5 DRD2
11 oculogyric crisis 31.6 DRD5 DRD4 DRD2
12 conduct disorder 31.6 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
13 dystonia 31.5 TH SLC6A3 SGCE DRD5 DRD2 DBH
14 personality disorder 31.5 TH SLC6A3 DRD4 DRD2 COMT BDNF
15 chronic tic disorder 31.4 SLITRK1 IMMP2L HDC DRD5 DRD4 DRD2
16 brain injury 31.4 DRD2 COMT BDNF
17 schizotypal personality disorder 31.3 DRD4 DRD2 COMT
18 bruxism 31.3 DRD5 DRD4 DRD2
19 stuttering 31.3 SLC6A3 DRD2 DBH CNTNAP2
20 sleep disorder 31.2 TH SLC6A3 DRD2 BDNF
21 bulimia nervosa 31.2 DRD4 DRD2 COMT BDNF
22 eating disorder 31.2 SLC6A3 DRD2 COMT BDNF
23 cervical dystonia 31.2 TH SGCE DRD5 BDNF
24 mental depression 31.2 SLC6A3 DRD4 DRD2 COMT BDNF
25 impulse control disorder 31.1 SLITRK1 SLC6A3 DRD5 DRD4 DRD2 COMT
26 oppositional defiant disorder 31.1 SLC6A3 DRD4 DRD2 DBH COMT
27 bipolar disorder 31.0 TH SLC6A3 DRD5 DRD4 DRD2 DBH
28 autism 31.0 TH SLC6A3 SLC1A3 IMMP2L DRD5 DRD4
29 substance abuse 31.0 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
30 major depressive disorder 30.9 SLC6A3 SLC1A3 DRD4 DRD2 COMT BDNF
31 alcohol use disorder 30.9 SLC6A3 DRD2 COMT BDNF
32 drug dependence 30.9 SLC6A3 DRD2 BDNF
33 bipolar i disorder 30.9 DRD4 DRD2 COMT BDNF
34 alcohol dependence 30.9 TH SLC6A3 DRD5 DRD4 DRD2 DBH
35 pervasive developmental disorder 30.9 TH SLC6A3 IMMP2L DRD5 DRD4 DRD2
36 migraine with or without aura 1 30.9 SLC6A3 SLC1A3 DRD5 DRD4 DRD2 DBH
37 autism spectrum disorder 30.8 SLC6A3 IMMP2L DRD5 DRD4 DRD2 DPP6
38 pathological gambling 30.8 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
39 generalized anxiety disorder 30.8 SLC6A3 DRD2 COMT BDNF
40 hypochondriasis 30.8 SLITRK1 BDNF
41 traumatic brain injury 30.7 DRD2 COMT BDNF
42 early-onset schizophrenia 30.7 DRD2 BDNF
43 restless legs syndrome 30.7 TH SLC6A3 DRD5 DRD4 DRD2 COMT
44 mood disorder 30.6 TH SLC6A3 DRD4 DRD2 COMT BDNF
45 substance dependence 30.6 SLC6A3 DRD5 DRD4 DRD2 COMT BDNF
46 anxiety 30.6 TH SLC6A3 DRD4 DRD2 COMT BDNF
47 cyclothymic disorder 30.6 DRD4 DRD2
48 neonatal hypoxic and ischemic brain injury 30.6 TH SLC1A3 BDNF
49 antisocial personality disorder 30.6 SLC6A3 DRD4 DRD2 COMT
50 hyperprolactinemia 30.6 DRD4 DRD2 DBH

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to Gilles De La Tourette Syndrome

Symptoms & Phenotypes for Gilles De La Tourette Syndrome

Human phenotypes related to Gilles De La Tourette Syndrome:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 sleep disturbance 31 HP:0002360
2 attention deficit hyperactivity disorder 31 HP:0007018
3 aggressive behavior 31 HP:0000718
4 echolalia 31 HP:0010529
5 obsessive-compulsive behavior 31 HP:0000722
6 self-mutilation 31 HP:0000742
7 motor tics 31 HP:0100034
8 phonic tics 31 HP:0100035

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
sleep disturbance
aggressive behavior
echolalia
obsessive-compulsive behavior
coprolalia
more

Clinical features from OMIM:

137580

UMLS symptoms related to Gilles De La Tourette Syndrome:


seizures, tremor, back pain, pain, headache, syncope, athetosis, chronic pain, sciatica, sleep disturbances, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 AADAC ADRA2A BDNF COMT DBH DPP6

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 ADRA2A BDNF BTBD9 CNTNAP2 COMT DBH
2 homeostasis/metabolism MP:0005376 10.07 ADRA2A BDNF BTBD9 COMT DBH DRD2
3 endocrine/exocrine gland MP:0005379 9.97 BDNF COMT DBH DRD2 DRD5 IMMP2L
4 nervous system MP:0003631 9.86 ADRA2A BDNF BTBD9 CNTNAP2 COMT DBH
5 integument MP:0010771 9.76 BDNF CNTNAP2 DBH DRD2 HDC IMMP2L
6 taste/olfaction MP:0005394 8.92 BDNF CNTNAP2 DRD2 SLC6A3

Drugs & Therapeutics for Gilles De La Tourette Syndrome

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
2
Clonidine Approved Phase 4 4205-90-7 2803
3
Haloperidol Approved Phase 4 52-86-8 3559
4
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
7
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
8
Levetiracetam Approved Phase 4 102767-28-2 441341
9
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
10
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
11
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
12
Ondansetron Approved Phase 4 99614-02-5 4595
13
Galantamine Approved Phase 4 357-70-0 9651
14
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
15 Adrenergic Agents Phase 4
16 Adrenergic alpha-2 Receptor Agonists Phase 4
17 Adrenergic Agonists Phase 4
18 Antihypertensive Agents Phase 4
19 Anticonvulsants Phase 4
20 GABA Agents Phase 4
21 Sympatholytics Phase 4
22 Analgesics Phase 4
23 Serotonin Uptake Inhibitors Phase 4
24 Haloperidol decanoate Phase 4
25 Cytochrome P-450 Enzyme Inhibitors Phase 4
26 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
28 Excitatory Amino Acid Antagonists Phase 4
29 Neuroprotective Agents Phase 4
30 Excitatory Amino Acid Agonists Phase 4
31 Excitatory Amino Acids Phase 4
32 Antimanic Agents Phase 4
33 Dopamine Agents Phase 4
34 Tranquilizing Agents Phase 4
35 Dopamine Antagonists Phase 4
36 Antipsychotic Agents Phase 4
37 Psychotropic Drugs Phase 4
38 Central Nervous System Depressants Phase 4
39 Dermatologic Agents Phase 4
40 Serotonin Receptor Agonists Phase 4
41 Dopamine agonists Phase 4
42 Serotonin Agents Phase 4
43 Serotonin 5-HT1 Receptor Agonists Phase 4
44 Antidepressive Agents Phase 4
45 Dopamine D2 Receptor Antagonists Phase 4
46 Serotonin Antagonists Phase 4
47 Serotonin 5-HT2 Receptor Antagonists Phase 4
48 Gastrointestinal Agents Phase 4
49 Anti-Anxiety Agents Phase 4
50 Antiemetics Phase 4

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT00152750 Phase 4 APO-clonidine
2 Guanfacine in Children With Tic Disorders: A Multi-site Study Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
3 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
4 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
5 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
6 Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
7 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
8 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
9 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
10 A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder Recruiting NCT03661983 Phase 4 Aripiprazole (OPC-14597);Placebo
11 Pilot Examination of Galantamine in the Management of Tic Disorders Terminated NCT00226824 Phase 4 galantamine
12 Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS Completed NCT00478842 Phase 3
13 Thalamic Deep Brain Stimulation for Tourette's Syndrome: a Pragmatic Trial With Brief Randomized, Double-blinded Sham Controlled Sequences Completed NCT03958617 Phase 2, Phase 3
14 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
15 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01416441 Phase 3 aripiprazole
16 Childhood Onset Psychiatric Disorders: A Placebo Controlled Double-Blind Crossover Trial of Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
17 Behavior Therapy for Children With Chronic Tic Disorders Completed NCT00218777 Phase 2, Phase 3
18 A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
19 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418339 Phase 3 aripiprazole;Placebo
20 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
21 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
22 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418352 Phase 3 aripiprazole 52.5 mg;Matching Placebo;Aripiprazole 77.5 mg;Aripiprazole 110 mg
23 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Safety and Efficacy of Topiramate in the Treatment of Tourette Syndrome (CAPSS-176) Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
24 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286) Completed NCT00206336 Phase 3 Topiramate (drug)
25 A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
26 A Multicenter, Randomized, Double-Blind, Flexible-Dosed, Placebo-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Tourette's Syndrome Recruiting NCT03487783 Phase 3 Aripiprazole Oral Solution;Placebo Oral Solution
27 A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders Recruiting NCT03087201 Phase 3 nabiximols;placebo
28 An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo
29 A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Active, not recruiting NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
30 A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome Active, not recruiting NCT03571256 Phase 3 deutetrabenazine Low;deutetrabenazine High;Placebo
31 Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome Terminated NCT00681863 Phase 3 pramipexole 0.125 mg BID;pramipexole 0.0625 mg QD;pramipexole 0.125 mg TID;pramipexole 0.25 mg BID;pramipexole 0.0625 mg BID
32 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Unknown status NCT02102698 Phase 2 Ecopipam
33 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome - A Pilot Study Unknown status NCT02112253 Phase 1, Phase 2
34 A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
35 A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
36 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Completed NCT02879578 Phase 2 NBI-98854
37 Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
38 A Randomised, Controlled, Crossover Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Severe Tourette Syndrome Completed NCT01647269 Phase 2
39 Ecopipam Treatment of Tourette Syndrome Completed NCT01244633 Phase 1, Phase 2 Ecopipam
40 Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
41 A Randomized, Double-blind, Placebo-controlled, Flexible Dose Study to Evaluate Efficacy and Safety of Pramipexole Immediate Release (0.125-0.5mg/Day) Versus Placebo for 6 Weeks in Children and Adolescents (Age 6-17 Inclusive) Diagnosed With Tourette Disorder According to DSM IV Criteria. Completed NCT00558467 Phase 2 pramipexole immediate release (IR);Placebo
42 Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
43 Thalamic Deep Brain Stimulation for Tourette Syndrome: A Prospective Clinical Trial Completed NCT00311909 Phase 2
44 Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome Completed NCT00529308 Phase 2
45 Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed NCT03444038 Phase 2 NBI-98854
46 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Adult Subjects With Tourette Syndrome Completed NCT02581865 Phase 2 NBI-98854;Placebo
47 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Completed NCT02679079 Phase 2 NBI-98854;Placebo
48 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed NCT03325010 Phase 2 Valbenazine;Placebo oral capsule
49 Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
50 Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome Completed NCT00004652 Phase 2 pimozide

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Clonidine
CLONIDINE HCL PWDR
Clonidine Hydrochloride
Haloperidol
haloperidol decanoate
Haloperidol lactate
Mecamylamine
Mecamylamine hydrochloride
Pergolide
Pergolide Mesylate
Perphenazine
Pimozide
Risperidone
ziprasidone
ziprasidone hydrochloride
Ziprasidone mesylate

Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

Genetic tests related to Gilles De La Tourette Syndrome:

# Genetic test Affiliating Genes
1 Tourette Syndrome 29 HDC SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

40
Brain, Eye, Cortex, Globus Pallidus, Testes, Thalamus, Colon

Publications for Gilles De La Tourette Syndrome

Articles related to Gilles De La Tourette Syndrome:

(show top 50) (show all 2978)
# Title Authors PMID Year
1
Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. 56 6 61
24411733 2014
2
L-histidine decarboxylase and Tourette's syndrome. 6 56
20445167 2010
3
Sequence variants in SLITRK1 are associated with Tourette's syndrome. 56 6
16224024 2005
4
Autosomal dominant myoclonus-dystonia and Tourette syndrome in a family without linkage to the SGCE gene. 61 54 56
17702041 2007
5
Disruption of the CNTNAP2 gene in a t(7;15) translocation family without symptoms of Gilles de la Tourette syndrome. 54 56 61
17392702 2007
6
CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. 54 56 61
12809671 2003
7
Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. 61 56 54
8703056 1996
8
Exome sequencing of a pedigree with Tourette syndrome or chronic tic disorder. 61 56
21520241 2011
9
Additional support for the association of SLITRK1 var321 and Tourette syndrome. 6 61
20351724 2010
10
Cerebellar morphology in Tourette syndrome and obsessive-compulsive disorder. 56 61
20437583 2010
11
The genetics of Tourette syndrome: a review. 61 56
19913658 2009
12
Association of intronic variants of the BTBD9 gene with Tourette syndrome. 61 56
19822783 2009
13
Lack of association between SLITRK1var321 and Tourette syndrome in a large family-based sample. 6 61
18413575 2008
14
Association of the Slit and Trk-like 1 gene in Taiwanese patients with Tourette syndrome. 61 56
18021920 2007
15
A large Italian family with Gilles de la Tourette syndrome: clinical study and analysis of the SLITRK1 gene. 56 61
17712845 2007
16
Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. 56 61
17083340 2006
17
Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. 61 6
17035247 2006
18
Chromosome 11-q24 region in Tourette syndrome: association and linkage disequilibrium study in the French Canadian population. 56 61
16158425 2005
19
Indications of linkage and association of Gilles de la Tourette syndrome in two independent family samples: 17q25 is a putative susceptibility region. 61 56
15303240 2004
20
Association between 7q31 markers and Tourette syndrome. 61 56
15103711 2004
21
Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder. 61 56
12698358 2003
22
Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype. 61 56
12682296 2003
23
Genomewide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. 61 56
11840360 2002
24
Candidate region for Gilles de la Tourette syndrome at 7q31. 61 56
11424142 2001
25
Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome. 56 61
11254443 2001
26
Breakpoint sequences of an 1;8 translocation in a family with Gilles de la Tourette syndrome. 61 56
11093278 2000
27
Significant linkage for Tourette syndrome in a large French Canadian family. 61 56
10986045 2000
28
A complete genome screen in sib pairs affected by Gilles de la Tourette syndrome. The Tourette Syndrome Association International Consortium for Genetics. 61 56
10521310 1999
29
Bilineal transmission in Tourette syndrome. 61 56
10489047 1999
30
Multiple childhood behavioral disorders (Tourette syndrome, multiple tics, ADD and OCD) presenting in a family with a balanced chromosome translocation (t1;8)(q21.1;q22.1). 61 56
10551546 1999
31
Genome scan for linkage to Gilles de la Tourette syndrome. 56 61
10402514 1999
32
Identification of genetic markers associated with Gilles de la Tourette syndrome in an Afrikaner population. 56 61
9718333 1998
33
Quest for the elusive genetic basis of Tourette syndrome. 61 56
8900223 1996
34
Tourette syndrome in a pedigree with a 7;18 translocation: identification of a YAC spanning the translocation breakpoint at 18q22.3. 61 56
8900226 1996
35
Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. 61 56
8751870 1996
36
Linkage analysis and exclusion of regions of chromosomes 3 and 8 in Gilles de la Tourette syndrome following the identification of a balanced reciprocal translocation 46 XY, t(3:8)(p21.3 q24.1) in a case of Tourette syndrome. 56 61
8902885 1996
37
Intermediate inheritance of Tourette syndrome, assuming assortative mating. 61 56
7668298 1995
38
Coprolalia in younger patients with Gilles de la Tourette syndrome. 56 61
7845402 1994
39
Samuel Johnson: victim of Gilles de la Tourette syndrome. 56 61
8270933 1993
40
The genetics of the Gilles de la Tourette syndrome: a review. 61 56
8478592 1993
41
Tourette syndrome and autistic disorder: a significant relationship. 61 56
2063921 1991
42
Clinical and genetic relationships between autism-pervasive developmental disorder and Tourette syndrome: a study of 19 cases. 56 61
2063922 1991
43
Progress in the search for genetic linkage with Tourette syndrome: an exclusion map covering more than 50% of the autosomal genome. 61 56
1990837 1991
44
A family study of Gilles de la Tourette syndrome. 56 61
1985456 1991
45
Possible linkage of Tourette syndrome to markers on short arm of chromosome 3 (C3p21-14) 56 61
1977057 1990
46
Blood serotonin and tryptophan in Tourette syndrome. 61 56
2389798 1990
47
No evidence for genetic linkage of Gilles de la Tourette syndrome on chromosomes 7 and 18. 61 56
2395161 1990
48
Hypothesis: homozygosity in Tourette syndrome. 56 61
2596529 1989
49
Tourette syndrome and neuropsychiatric disorders: is there a genetic relationship? 56 61
3165247 1988
50
A controlled study of Tourette syndrome-Revisited: A reply to the letter of Pauls et al. 56 61
17948588 1988

Variations for Gilles De La Tourette Syndrome

ClinVar genetic disease variations for Gilles De La Tourette Syndrome:

6 (show top 50) (show all 59) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SLITRK1 NM_052910.2(SLITRK1):c.1264del (p.Leu422fs)deletion Pathogenic 1578 rs193302861 13:84454379-84454379 13:83880244-83880244
2 SLITRK1 NM_052910.2(SLITRK1):c.*689G>ASNV Pathogenic 1579 rs191284403 13:84452863-84452863 13:83878728-83878728
3 HDC NM_002112.4(HDC):c.951G>A (p.Trp317Ter)SNV Pathogenic 14912 rs267606861 15:50544717-50544717 15:50252520-50252520
4 SLITRK1 NM_052910.2(SLITRK1):c.*1882A>TSNV Uncertain significance 312479 rs886050327 13:84451670-84451670 13:83877535-83877535
5 SLITRK1 NM_052910.2(SLITRK1):c.*1572C>GSNV Uncertain significance 312480 rs368937569 13:84451980-84451980 13:83877845-83877845
6 SLITRK1 NM_052910.2(SLITRK1):c.*1149dupduplication Uncertain significance 312483 rs886050328 13:84452403-84452403 13:83878268-83878268
7 SLITRK1 NM_052910.2(SLITRK1):c.*575C>TSNV Uncertain significance 312491 rs886050329 13:84452977-84452977 13:83878842-83878842
8 SLITRK1 NM_052910.2(SLITRK1):c.913C>G (p.Pro305Ala)SNV Uncertain significance 312503 rs867766209 13:84454730-84454730 13:83880595-83880595
9 SLITRK1 NM_052910.2(SLITRK1):c.-245dupduplication Uncertain significance 312513 rs771177138 13:84455887-84455887 13:83881752-83881752
10 SLITRK1 NM_052910.2(SLITRK1):c.-270deldeletion Uncertain significance 312515 rs886050341 13:84455912-84455912 13:83881777-83881777
11 SLITRK1 NM_052910.2(SLITRK1):c.-584T>GSNV Uncertain significance 312520 rs886050344 13:84456226-84456226 13:83882091-83882091
12 SLITRK1 NM_052910.2(SLITRK1):c.-729G>CSNV Uncertain significance 312526 rs774658734 13:84456371-84456371 13:83882236-83882236
13 SLITRK1 NM_052910.2(SLITRK1):c.*2186T>ASNV Uncertain significance 312474 rs886050326 13:84451366-84451366 13:83877231-83877231
14 SLITRK1 NM_052910.2(SLITRK1):c.*2087T>CSNV Uncertain significance 312475 rs182027644 13:84451465-84451465 13:83877330-83877330
15 SLITRK1 NM_052910.2(SLITRK1):c.*761G>ASNV Uncertain significance 312489 rs144800086 13:84452791-84452791 13:83878656-83878656
16 SLITRK1 NM_052910.2(SLITRK1):c.*544C>ASNV Uncertain significance 312492 rs560253600 13:84453008-84453008 13:83878873-83878873
17 SLITRK1 NM_052910.2(SLITRK1):c.*67G>ASNV Uncertain significance 312495 rs568619249 13:84453485-84453485 13:83879350-83879350
18 SLITRK1 NM_052910.2(SLITRK1):c.2035A>C (p.Asn679His)SNV Uncertain significance 312497 rs886050332 13:84453608-84453608 13:83879473-83879473
19 SLITRK1 NM_052910.2(SLITRK1):c.1969T>C (p.Ser657Pro)SNV Uncertain significance 312498 rs886050333 13:84453674-84453674 13:83879539-83879539
20 SLITRK1 NM_052910.2(SLITRK1):c.1492A>G (p.Lys498Glu)SNV Uncertain significance 312500 rs886050334 13:84454151-84454151 13:83880016-83880016
21 SLITRK1 NM_052910.2(SLITRK1):c.1122C>T (p.Leu374=)SNV Uncertain significance 312501 rs749904055 13:84454521-84454521 13:83880386-83880386
22 SLITRK1 NM_052910.2(SLITRK1):c.1094G>A (p.Ser365Asn)SNV Uncertain significance 312502 rs886050335 13:84454549-84454549 13:83880414-83880414
23 SLITRK1 NM_052910.2(SLITRK1):c.294T>C (p.Val98=)SNV Uncertain significance 312504 rs751143571 13:84455349-84455349 13:83881214-83881214
24 SLITRK1 NM_052910.2(SLITRK1):c.117C>T (p.His39=)SNV Uncertain significance 312505 rs371889710 13:84455526-84455526 13:83881391-83881391
25 SLITRK1 NM_052910.2(SLITRK1):c.-70G>CSNV Uncertain significance 312506 rs140875495 13:84455712-84455712 13:83881577-83881577
26 SLITRK1 NM_052910.2(SLITRK1):c.-178A>GSNV Uncertain significance 312507 rs144821830 13:84455820-84455820 13:83881685-83881685
27 SLITRK1 NM_052910.2(SLITRK1):c.-242_-241dupduplication Uncertain significance 312511 rs886050338 13:84455883-84455884 13:83881748-83881749
28 SLITRK1 NM_052910.2(SLITRK1):c.-531C>GSNV Uncertain significance 312517 rs551901006 13:84456173-84456173 13:83882038-83882038
29 SLITRK1 NM_052910.2(SLITRK1):c.-551A>GSNV Uncertain significance 312519 rs867815028 13:84456193-84456193 13:83882058-83882058
30 SLITRK1 NM_052910.2(SLITRK1):c.-697C>TSNV Uncertain significance 312525 rs536165638 13:84456339-84456339 13:83882204-83882204
31 SLITRK1 NM_052910.2(SLITRK1):c.-853C>GSNV Uncertain significance 312528 rs886050347 13:84456495-84456495 13:83882360-83882360
32 SLITRK1 NM_052910.2(SLITRK1):c.*1017G>ASNV Uncertain significance 312486 rs142645261 13:84452535-84452535 13:83878400-83878400
33 SLITRK1 NM_001281503.2(SLITRK1):c.*854_*858ATTTT[2]short repeat Uncertain significance 312487 rs528376884 13:84452684-84452688 13:83878549-83878553
34 SLITRK1 NM_052910.2(SLITRK1):c.*230T>GSNV Uncertain significance 312493 rs886050330 13:84453322-84453322 13:83879187-83879187
35 SLITRK1 NM_052910.2(SLITRK1):c.*167C>GSNV Uncertain significance 312494 rs886050331 13:84453385-84453385 13:83879250-83879250
36 SLITRK1 NM_052910.2(SLITRK1):c.1538G>A (p.Gly513Glu)SNV Uncertain significance 312499 rs200447166 13:84454105-84454105 13:83879970-83879970
37 SLITRK1 NM_052910.2(SLITRK1):c.-240dupduplication Uncertain significance 312508 rs886050336 13:84455882-84455882 13:83881747-83881747
38 SLITRK1 NM_052910.2(SLITRK1):c.-244deldeletion Uncertain significance 312512 rs886050339 13:84455886-84455886 13:83881751-83881751
39 SLITRK1 NM_052910.2(SLITRK1):c.-536A>TSNV Uncertain significance 312518 rs886050343 13:84456178-84456178 13:83882043-83882043
40 SLITRK1 NM_052910.2(SLITRK1):c.-696A>GSNV Uncertain significance 312524 rs886050346 13:84456338-84456338 13:83882203-83882203
41 SLITRK1 NM_052910.2(SLITRK1):c.-744dupduplication Uncertain significance 312527 rs563861788 13:84456386-84456386 13:83882251-83882251
42 SLITRK1 NM_052910.2(SLITRK1):c.*1944A>GSNV Uncertain significance 312478 rs543615109 13:84451608-84451608 13:83877473-83877473
43 SLITRK1 NM_052910.2(SLITRK1):c.*1313C>GSNV Uncertain significance 312481 rs140472390 13:84452239-84452239 13:83878104-83878104
44 SLITRK1 NM_052910.2(SLITRK1):c.*649A>GSNV Uncertain significance 312490 rs57857456 13:84452903-84452903 13:83878768-83878768
45 SLITRK1 NM_052910.2(SLITRK1):c.*23G>ASNV Uncertain significance 312496 rs200497030 13:84453529-84453529 13:83879394-83879394
46 SLITRK1 NM_052910.2(SLITRK1):c.-240deldeletion Uncertain significance 312509 rs886050337 13:84455882-84455882 13:83881747-83881747
47 SLITRK1 NM_052910.2(SLITRK1):c.-241dupduplication Uncertain significance 312510 rs886050338 13:84455883-84455883 13:83881748-83881748
48 SLITRK1 NM_052910.2(SLITRK1):c.-266deldeletion Uncertain significance 312514 rs886050340 13:84455908-84455908 13:83881773-83881773
49 SLITRK1 NM_052910.2(SLITRK1):c.-278G>ASNV Uncertain significance 312516 rs886050342 13:84455920-84455920 13:83881785-83881785
50 SLITRK1 NM_052910.2(SLITRK1):c.-589A>GSNV Uncertain significance 312521 rs886050345 13:84456231-84456231 13:83882096-83882096

Copy number variations for Gilles De La Tourette Syndrome from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 60595 11 88300000 92800000 Copy number GRM5 Tourette syndrome
2 97401 16 1 7900000 Copy number A2BP1 Tourette syndrome
3 107550 17 15900000 22100000 Microdeletion Tourette syndrome
4 161233 22 17900000 22200000 Duplication COMT Tourette syndrome
5 204047 6 105500000 114600000 Copy number NKAIN2 Tourette syndrome
6 218083 7 107400000 127100000 Copy number IMMP2L Tourette syndrome
7 221370 7 143100000 147900000 Copy number CNTNAP2 Tourette syndrome
8 222485 7 152600000 155100000 Copy number DPP6 Tourette syndrome
9 257157 X 1 4300000 Deletion NLGN4 Tourette syndrome

Expression for Gilles De La Tourette Syndrome

Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for Gilles De La Tourette Syndrome

Pathways related to Gilles De La Tourette Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Histidine metabolism hsa00340

Pathways related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 TH SLC6A3 SLC1A3 DRD5 DRD4 DRD2
2 12.34 TH SLC1A3 DBH COMT CNTNAP2
4
Show member pathways
11.71 TH DRD4 DRD2
5
Show member pathways
11.69 TH SLC6A3 DRD2 BDNF
6 11.63 TH HDC DBH
7
Show member pathways
11.6 DRD5 DRD4 DRD2 ADRA2A
8 11.55 TH SLC1A3 BDNF
9
Show member pathways
11.51 TH DBH COMT
10
Show member pathways
11.18 TH SLC6A3 DBH
11 10.84 TH DRD2
12 10.66 TH COMT
13
Show member pathways
10.6 TH HDC DBH COMT
14
Show member pathways
10.59 TH SLC6A3 DRD5 DRD4 DRD2 DBH

GO Terms for Gilles De La Tourette Syndrome

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.03 SLITRK1 SLC6A3 SLC1A3 SGCE IMMP2L GTSCR1
2 integral component of plasma membrane GO:0005887 9.87 SLC6A3 SLC1A3 SGCE DRD5 DRD4 DRD2
3 axon GO:0030424 9.43 TH SLC6A3 DRD2 COMT CNTNAP2 BDNF
4 dopaminergic synapse GO:0098691 9.26 SLC6A3 DRD2
5 dendrite GO:0030425 9.17 TH SGCE DRD4 DRD2 COMT CNTNAP2

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 TH SLC6A3 SLC1A3 DRD2 COMT
2 chemical synaptic transmission GO:0007268 9.94 SLC1A3 DRD5 DRD4 DBH
3 response to ethanol GO:0045471 9.85 TH SLC6A3 DRD2
4 memory GO:0007613 9.82 TH DBH BDNF
5 learning GO:0007612 9.79 TH COMT CNTNAP2
6 synapse assembly GO:0007416 9.78 SLITRK1 DRD2 BDNF
7 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.77 DRD5 DRD2 ADRA2A
8 social behavior GO:0035176 9.75 TH DRD4 CNTNAP2
9 response to nicotine GO:0035094 9.74 TH SLC6A3 DRD2
10 response to cocaine GO:0042220 9.73 SLC6A3 DRD5 DRD2
11 locomotory behavior GO:0007626 9.73 TH SLC6A3 DRD2 DBH
12 response to pain GO:0048265 9.68 DBH COMT
13 dopamine receptor signaling pathway GO:0007212 9.68 DRD4 DRD2
14 behavioral response to cocaine GO:0048148 9.68 DRD4 DRD2
15 response to iron ion GO:0010039 9.68 SLC6A3 DRD2
16 transmission of nerve impulse GO:0019226 9.67 DRD5 CNTNAP2
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD4 DRD2
18 adult behavior GO:0030534 9.67 SLITRK1 DRD2 CNTNAP2
19 prepulse inhibition GO:0060134 9.66 SLC6A3 DRD2
20 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.66 DRD5 DRD2
21 neurotransmitter biosynthetic process GO:0042136 9.65 TH SLC6A3
22 striatum development GO:0021756 9.65 DRD2 CNTNAP2
23 associative learning GO:0008306 9.65 DRD5 DRD2 DBH
24 dopamine biosynthetic process GO:0042416 9.64 TH SLC6A3
25 regulation of dopamine metabolic process GO:0042053 9.63 SLC6A3 DRD4
26 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.63 DRD4 DRD2
27 response to light stimulus GO:0009416 9.63 TH SLC1A3 DRD2
28 adenohypophysis development GO:0021984 9.62 SLC6A3 DRD2
29 mating behavior GO:0007617 9.61 TH DRD5
30 norepinephrine biosynthetic process GO:0042421 9.59 TH DBH
31 auditory behavior GO:0031223 9.58 SLC1A3 DRD2
32 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.58 DRD5 DRD2 ADRA2A
33 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.54 DRD4 DRD2
34 behavioral response to ethanol GO:0048149 9.54 DRD4 DRD2 DBH
35 fear response GO:0042596 9.52 DRD4 DBH
36 response to histamine GO:0034776 9.51 DRD4 DRD2
37 dopamine metabolic process GO:0042417 9.5 DRD4 DRD2 COMT
38 dopamine catabolic process GO:0042420 9.43 SLC6A3 DBH COMT
39 catecholamine biosynthetic process GO:0042423 9.33 TH HDC DBH
40 synaptic transmission, dopaminergic GO:0001963 9.26 TH DRD5 DRD4 DRD2
41 response to amphetamine GO:0001975 9.02 TH DRD5 DRD4 DRD2 DBH

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.58 SLC6A3 DRD4 DRD2
2 amino acid binding GO:0016597 9.43 TH SLC1A3
3 epinephrine binding GO:0051379 9.37 DRD4 ADRA2A
4 adrenergic receptor activity GO:0004935 9.33 DRD5 DRD2 ADRA2A
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD4 DRD2
6 norepinephrine binding GO:0051380 9.26 DRD4 ADRA2A
7 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD5 DRD4 DRD2
8 dopamine binding GO:0035240 9.02 TH SLC6A3 DRD5 DRD4 DRD2

Sources for Gilles De La Tourette Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....